Back to results

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (TREND)

Primary Purpose

Age-related Macular Degeneration, Choroidal Neovascularization

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

Ranibizumab 0.5mg

About this trial

This is an interventional supportive care trial for Age-related Macular Degeneration focused on measuring Ranibizumab, Lucentis, choroidal neovascularization, age-related macular degeneration, treat and extend regimen

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

Male or female patients, ≥50 years of age with signed informed consent before study procedures
Visual impairment predominantly due to nAMD.
Active CNV secondary to AMD confirmed by presence of active leakage from CNV seen by fluorescein angiography (FA) and/or color fundus photography
Presence of intra- or subretinal fluid/hemorrhage seen by SD-OCT
BCVA score must be ≤ 78 and ≥ 23 letters at 4 meters starting distance using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity charts (approximate Snellen equivalent of 20/32 and 20/320)

Key Exclusion Criteria:

Any type of advanced, severe or unstable disease, including any medical condition (controlled or uncontrolled) that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk.
Stroke or myocardial infarction within 3 months prior to Screening.
Any active periocular or ocular infection or inflammation in both eyes.
Ocular disorders in the study eye at the time of enrollment that may confound interpretation of study results and compromise visual acuity.
Presence of amblyopia or amaurosis in the fellow eye.
History of treatment with any anti-angiogenic drugs (including any anti- vascular endothelial growth factor (anti-VEGF) agents) e.g., bevacizumab [Avastin®], aflibercept [Eylea®]) or vPDT in the study eye.
History of intravitreal treatment with corticosteroids within 6 months and history of intra-ocular surgery within 3 months in the study eye prior to the Screening.
Pregnant or nursing (lactating) women. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Arm Label

Group I ranibizumab 0.5 mg monthly

Group II ranibizumab 0.5 mg TER

Arm Description

Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11

Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11

Outcomes

Primary Outcome Measures

Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement

Secondary Outcome Measures

Number of Visits Scheduled

The number of visits scheduled according to the treat and extend regimen after treatment initiation

Change in BCVA From Baseline to Month 12

Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters

Average BCVA Change From Baseline to Month 12

Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from Baseline to Month 12

Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and compare to Baseline

Number of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 12 as compared with baseline

Number of Patients With Best Corrected Visual Acuity (BCVA) Loss <5, <10, and <15 Letters by Visit

Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.

Number of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12

Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 12 indicates a positive outcome

The Mean Number of Treatment Frequency

The number of injections received

The Average Number of Days Between Injections

The average dosing interval was measured as the average number of days between injections

Percentage of Participants With Fluid Free Macula Over Time up to Month 12

OCT (optical coherence tomography) was used to assess intra-retinal fluid as Measured by SD-OCT (Spectral Domain-Optical Coherence Tomography). Fluid free macula refers to absence of macular edema (as assessed by the reading center). The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the macular edema (center involvement) at study completion. These total counts are used as the denominator for the percentages

Change in Central Subfield Retinal Thickness (CSFT) Over Time

OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit

Percentage of Patients With Choroidal Neovascularization (CNV) Leakage Assessed by Fluorescein Angiography (FA) in the Study Eye at

To evaluate presence of active CNV leakage on fluorescein angiography (FA) by reading center over time up to Month 12. The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the presence of leakage at study completion. These total counts are used as the denominator for the percentages.

Change From Baseline in Composite Score of the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)

The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also ranged from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome

Full Information

NCT ID

NCT01948830

First Posted

September 19, 2013

Last Updated

March 16, 2017

Sponsor

Novartis Pharmaceuticals

1. Study Identification

Unique Protocol Identification Number

NCT01948830

Brief Title

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

Acronym

TREND

Official Title

A 12-month, Phase 3b, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular Age-related Macular Degeneration

Study Type

Interventional

2. Study Status

Record Verification Date

March 2017

Overall Recruitment Status

Completed

Study Start Date

December 17, 2013 (Actual)

Primary Completion Date

November 19, 2015 (Actual)

Study Completion Date

November 19, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Novartis Pharmaceuticals

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration

Detailed Description

This was a 12-month, phase IIIb, randomized, Visual Acuity assessor-masked, multi-center, interventional study assessing the efficacy and safety of the TER vs monthly regimens of 0.5 mg ranibizumab intravitreal (IVT) injections in patients with newly diagnosed nAMD. Patients will be randomized 1:1 into one of two treatment arms, Treat and Extend or monthly regimens. There will be 3 periods in this study: Screening period (up to 14days), treatment period (11 months), follow-up period (1 month). At randomization visit patients will be randomized into one of the 2 treatment groups Group I ranibizumab 0.5 mg based on monthly treatment or Group II ranibizumab 0.5 mg based on TER (randomization ratio of 1:1) and will receive the first dose of Investigational treatment. Patients in Group I the following visits will perform on monthly intervals. For patients in Group II the investigator will evaluate disease activity (i.e., signs of exudation) based on SD-OCT, and in case of absence of disease activity every next visit will be 2 weeks), with a maximum of a 12-week interval.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Age-related Macular Degeneration, Choroidal Neovascularization

Keywords

Ranibizumab, Lucentis, choroidal neovascularization, age-related macular degeneration, treat and extend regimen

7. Study Design

Primary Purpose

Supportive Care

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

Outcomes Assessor

Allocation

Randomized

Enrollment

650 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Group I ranibizumab 0.5 mg monthly

Arm Type

Active Comparator

Arm Description

Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11

Arm Title

Group II ranibizumab 0.5 mg TER

Arm Type

Active Comparator

Arm Description

Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11

Intervention Type

Drug

Intervention Name(s)

Ranibizumab 0.5mg

Other Intervention Name(s)

Lucentis

Intervention Description

0.5 mg ranibizumab (intravitreal injections) prefilled syringe)

Intervention Type

Drug

Intervention Name(s)

Ranibizumab 0.5mg

Other Intervention Name(s)

Lucentis

Intervention Description

0.5 mg ranibizumab (intravitreal injections) prefilled syringe)

Primary Outcome Measure Information:

Title

Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12

Description

Time Frame

Baseline to month 12

Secondary Outcome Measure Information:

Title

Number of Visits Scheduled

Description

The number of visits scheduled according to the treat and extend regimen after treatment initiation

Time Frame

From Month1 to Month 11

Title

Change in BCVA From Baseline to Month 12

Description

Time Frame

Baseline to Month 12

Title

Average BCVA Change From Baseline to Month 12

Description

Time Frame